Glycoforms of recombinant human follicle stimulating hormone (rhFSH) (Org 32489, Puregon®) were characterized using concanavalin A lectin affinity chromatography to reveal information about the internal carbohydrate complexity (extent of carbohydrate side-chain branching) of the preparations. The rhFSH glycoforms were measured by radioimmunoassay and a two-site immunoradiometric assay and compared with those in two urinary preparations (Metrodin and Metrodin-HP) used in assisted reproduction programmes and a urinary FSH international standard 70/45 (uFSH IS 70/45). Similar data were obtained with both assays; rhFSH had 6% complex internal carbohydrate structures compared with 22-27% for Metrodin, Metrodin-HP and uFSH. The proportion of simple carbohydrate structures was also different, with rhFSH having 18.5 compared with 4.5-9.3% for Metrodin, Metrodin-HP and uFSH. A linear relationship was observed between the percentage glycoforms with an isoelectric point (pi) <4 and the log percentage simple forms (logarithmic regression; r = 0.93) indicating a direct relationship between carbohydrate complexity and charge heterogeneity. In summary, rhFSH contains fewer complex forms and an increased proportion of simple carbohydrate structures in comparison with Metrodin, Metrodin-HP and IS 70/45.
Introduction
Follicle stimulating hormone (FSH), in common with other glycoproteins, luteinizing hormone (LH), thyroid stimulating hormone (TSH) and human chorionic gonadotrophin (HCG), exhibits heterogeneity mainly in terms of carbohydrate structures, particularly sialic acid, attached to the protein core (Ulloa-Aguirre et al, 1995) . The physiological significance of these glycoforms remains unclear although they have different in-vivo half-lives which may influence their bioactivity (Stockell-Hartree and Renwick, 1992) . However, they are known to vary in relation to the stage of the menstrual cycle with a relative increase in the proportion of less acidic serum FSH glycoforms during the late follicular phase and mid-cycle (Padmanabhan et al, 1988; Wide and Bakos, 1993; Zambrano et al., 1995) , probably related to the high oestrogenic milieu and increased gonadotrophin-releasing hormone (GnRH) secretion at that time. Other studies on glycoform distributions have used lectin affinity chromatography (Papandreou et al., 1993; Creus et al., 1996) and have demonstrated that FSH secreted during the menopause contains less branched glycoforms (more simple forms) compared with that secreted during the follicular phase of the normal menstrual cycle. Our work on human FSH (Lambert et al., 1995) indicated that the more alkaline forms have an increased bioactivity and Padmanabhan (1995) has reported that the different FSH glycoforms may encode for different biological functions. In addition, 15 FSH forms isolated from human pituitary extracts possessed a 5-fold range in specific activity by radioreceptor assay, again indicative of a functional difference between the glycoforms (Stanton et al., © European Society for Human Reproduction and Embryology 1992). In summary, it is now becoming clear that the internal carbohydrate branching and overall charge of the glycoforms of FSH are under endocrine control and represent a further subtle mechanism by which in-vivo bioactivity is modulated.
The production of recombinant human gonadotrophins represents a significant advance in assisted reproduction as they have advantages over existing urinary preparations, e.g. continual production of unlimited quantities of greater consistency and purity batch to batch (Howies, 1996; Olivje et al., 1996) . The use of recombinant human FSH in assisted reproduction programmes has recently been reviewed (Loumaye et al., 1995) . Recent clinical trials with two different recombinant human FSH preparations (Puregon®; Organon and Gonal F®; Serono) have demonstrated the efficacy of these preparations compared to urinary FSH during in-vitro fertilization (IVF) treatment (Out et al, 1995; Recombinant human FSH Study Group, 1995) . In view of the likelihood that alterations in carbohydrate structures may affect in-vivo bioactivity, we recently examined the glycoform distribution of a variety of FSH preparations currently used in assisted reproduction programmes and found the charge heterogeneity of recombinant human FSH (rhFSH, Puregon) glycoforms to be similar to follicular and luteal phase glycoforms (Lambert et al, 1995) . We have now extended our studies on the physico/chemical characterization of rhFSH to an investigation of the complexity of internal carbohydrate branching of this compound using concanavalin A chromatography, and compared this characterization with two urinary FSH (uFSH) preparations (Metrodin and Metrodin-HP) currently used in assisted reproduction programmes. 
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Materials and methods
Chemicals
Preparation of solutions for concanavalin-A affinity chromatography
Phosphate buffer [0.05 M, pH 7.4, containing 0.1% bovine serum albumin (BSA, ICN Biochemicals, High Wycombe, Bucks, UK)] was used to prepare all eluents. Eluent 1 was phosphate buffer only, eluent 2 was phosphate buffer containing 10 mM a-D-methylglucopyranoside (a-MG; Sigma Chemical Company, St Louis, MO, USA) and eluent 3 was phosphate buffer containing 300 mM a-D-methylmannopyranoside (a-MM; Sigma Chemical Company). Column regeneration solution 1 was 0.1 M borate (pH 8.5), regeneration solution 2 was 0.1 M sodium acetate/1 M sodium chloride (pH 4.5) and the column prewash solution consisted of 1 M sodium chloride, 5 mM calcium chloride dihydrate, 5 mM magnesium chloride and 5 mM manganese (II) chloride (all chemicals from BDH Chemicals Limited, Poole, Dorset, UK). The storage and equilibration buffer was phosphate buffer only.
Concanavalin A affinity chromatography procedure
Concanavalin A (Con A) interacts with A'-linked oligosaccharide structures according to their branching properties such that triantennary, tetra-antennary and bisecting oligosaccharides (complex forms) do not bind to Con A, biantennary and truncated hybrids (intermediate complexity forms) bind weakly and high mannose and hybrid oligosaccharide (simple forms) firmly bind to Con A (Cummings and Komfeld, 1982) .
Before use, the lectin columns (2.5ml Con A agarose, Sigma Chemical Co.) were equilibrated with five column volumes of prewash solution followed by 0.05 M phosphate buffer. Either 1 IU/100 [i\ of international reference preparation FSH 70/45 (urinary), recombinant FSH (Org 32489), Metrodin or Metrodin-HP, all prepared in Dulbecco's modification of Eagle's medium (DMEM) containing 0.1% BSA were loaded onto the column and allowed to interact for 10 min at room temperature. Unbound FSH was collected by passing 5 ml of eluent 1 down the column in 0.5 ml fractions. Weakly and firmly bound FSH was collected in a similar way by passing 25 ml of eluent 2 and 13 ml of eluent 3 respectively down the column. A total of 86 fractions were collected and stored frozen at -40°C for subsequent FSH immunoassay. Recoveries ranged from 73-113% (91.7 ± 2.6, mean ± SEM, n = 18). The column was regenerated using five column volumes of regeneration solutions 1 and 2 in sequence followed by prewash solution. The column was stored capped and upright in 0.05 M phosphate buffer at 4°C.
FSH radioimmunoassay
The matrix of the FSH standard IS 70/45 was adjusted to be identical to that of the fractions (i.e. 0.05 M phosphate buffer, pH 7.4 containing 0.1% BSA). Every 10th fraction was assayed at multiple dilutions in order to check parallelism. All fractions tested diluted in a parallel manner. FSH was measured by competitive double-antibody radioimmunoassay using lyophilized [ l25 I]-labelled FSH and rabbit antihuman pituitary FSH polyclonal antibody, code F87/2 (Chelsea Reagents, Hammersmith Hospital, London, UK). The crossreactivities of the anti-serum on a weight for weight basis, at 50% binding using IRP 78/549 were HCG 9.7% and fi-HCG 15%. The solid phase second antibody consisted of donkey anti-rabbit (dAR) immunoglobulin (Ig)G antibodies bound to sac-eel (IDS, Boldon, Tyne and Wear, UK). Quality control samples (0.75, 15 and 30 IU/1) were assayed in duplicate in each assay. Intra-assay and interassay coefficients of variation respectively were <9 and <10% over the range 0.39-50 IU/1.
FSH immunoradiometric assay
FSH was measured using a non-competitive in-house immunoradioassay. The standards and quality controls used were those prepared for the FSH radioassay. Parallelism was assessed in a similar way to that described for the FSH radioassay and there was no evidence for non-parallelism in the assay. The antibody label consisted of intact FSH [ 125 I]-labelled antibody (Serotech Ltd) and the solid phase second antibody was a polyclonal anti-FSH antibody (SAPU) linked to dynospheres (Dynal, Liverpool, UK). The cross-reactivity with LH, HCG and TSH was <0.1%. Quality control samples (0.75, 15 and 30 IU/1) were assayed in duplicate in each assay. Intra-assay and interassay coefficients of variation were <9 and <10% over the range 0.39-50 IU/1.
FSH immunoradioassay/radioassay ratio
The immunoradioassay/radioassay ratios were similar (P >0.05) for each FSH preparation before separation giving a ratio of 1.19 ± 0.12 (mean ± SEM, n = 9). The glycoform profiles for each FSH preparation were also similar when assessed by both radioassay and immunoradioassay.
Buffer interference
Interference of the sugars (10 mM a-MG and 300 mM a-MM) was assessed in both the immunoradioassay (I) and the radioassay (R). A series of rhFSH standards (2, 8 and 32 IU/1) was prepared in 0.05 M phosphate buffer containing 0.1% BSA alone or in combination with 10 mM a-MG or 300 mM a-MM. In four separate experiments there were no differences between R-rhFSH concentrations found in phosphate buffer or phosphate buffer containing 10 mM a-MG or 300 mm a-MM suggesting that these sugars do not interfere in the radioimmunoassay. Similarly, there were no differences between IrhFSH concentrations in phosphate buffer or phosphate buffer containing 10 mm a-MG. However, I-rhFSH concentrations were 31% (2 IU/1 rhFSH), 32% (8 IU/1 rhFSH) and 50% (32 IU/1 rhFSH) lower in the presence of 300 mM a-MM. Interference by the sugar ceased at dilutions of 1:4 and above (i.e. <75 mM a-MM) and for all subsequent experiments fractions were diluted >1:4 before assay.
Column capacity
The column capacity (overload) was assessed by determining the recovery of the unbound rhFSH (complex band) passed down a second fresh column; rhFSH (1 IU) was placed on a Con A column and 6 ml of phosphate buffer was passed down the column to remove the unbound FSH fraction. The amount of FSH in this fraction was then measured by immunoradioassay and the remaining material was passed down a second fresh column. The recovery from this column was 85%, indicating that the capacity of the column to bind FSH is not exceeded when 1 IU of rhFSH is eluted under the conditions described. Padmanabhan et al. (1988) . Data on pi of the preparations were taken from Lambert et al. (1995) . I-uFSH (mean ± SEM, three separate experiments) was 24.3 ± 1.8 (complex structures), 68.7 ± 2.3 (intermediate structures) and 7.0 ± 0.6 (simple structures). There were no differences in the proportion of each form detected by immunoradioimmunoassay and radioimmunoassay (all P >0.05) within each carbohydrate class. The total recovery of uFSH (mean ± SEM, three separate experiments) was 100.7 ± 4.6 (I) and 101.3 ± 4.4% (R) respectively.
Reproducibility of lectin affinity chromatography procedure
Statistical analysis
Combined data from separate experiments were presented as the mean ± SEM. Statistical significance of combined data was determined by single sample Student's Mest and differences were significant when P <0.05.
Results
The distribution of FSH glycoforms as measured by radioimmunoassay, following lectin affinity chromatography of rhFSH (Org 32489), Metrodin, Metrodin-HP and urinary IS 70/45 is shown in Figure 1 . The percentages of the carbohydrate classes (complex, intermediate and simple) for each preparation are given in Table I . There was a wide range of complexities in the intermediate class of all four preparations as shown by the tailing peak (Figure 1 ), which never fully returned to baseline. Furthermore, rhFSH contained a relatively high proportion of simple glycoforms (18.5 ± 3.5%) compared with the other preparations (<10%). Conversely, it had far fewer (6 ± 1 %) complex forms (P <0.05) compared with the other preparations (>21%). The glycosylation variants separated by internal carbohydrate complexity were compared to those separated on the basis of charge (by chromatofocusing, Lambert et al., 1995) . A linear relationship was observed (Figure 2 ) between the percentage glycoforms with an isoelectric point (pi) <4 and the log percentage simple forms (logarithmic regression; r = 0.93).
Discussion
Puregon (rhFSH) has proven to be more efficacious in large scale clinical trials (Out et al, 1995) producing a higher number of oocytes and slightly increased pregnancy rates compared with uFSH during standard IVF treatment. Although current therapeutic strategies are aimed at controlled multifollicular development, a different therapy regimen might involve a more physiological approach with the aim of developing one or two quality follicles and oocytes. Towards this end, we have been characterizing rhFSH (Puregon) to understand further the relationship between glycoform distribution and bioactivity (Lambert et al, 1995) and its similarity to FSH glycoforms which occur naturally during follicular development.
In this study we have compared the structural properties of Puregon with purified uFSH preparations used in assisted reproduction. We found that the internal carbohydrate structure of rhFSH contains far fewer complex forms i.e. triantennary, tetraantennary and bisecting oligosaccharides (6 versus 22-27% for the three urinary preparations) and an increased proportion of simple forms i.e. high mannose and hybrid oligosaccharides (18.5 versus 5-9%). Interestingly, in a previous study (Hard et al. 1990) , rhFSH (Puregon) and urinary hFSH were found to have a very similar monosaccharide composition with only small variations in the amounts of GlcNAc and N-acetyl neuraminic acid. Further they reported a much higher proportion of complex forms (>25%) to be present in Puregon than indicated by our results (6%), although this discrepancy may relate to the very different technical procedures employed in the two studies (enzymatic release of the oligosaccharides followed by separation by gel permeation chromatography and fractionation by a combination of FPLC and HPLC (Hard et al., 1990) compared with concanavalin A chromatography as used in the present study. Endogenous FSH in the late (day 13) follicular phase contains a relatively high proportion (45%) of complex carbohydrate glycoforms and no simple forms (Creus et al, 1996) . Likewise, Papandreou et al. (1993) found that >80% of FSH from their normal control group (five women in the follicular phase, day of cycle not reported) existed as complex forms. The difference between the glycoform composition in natural serum FSH and the non-recombinant preparations examined in the present study undoubtedly relates to the source of that FSH, i.e urine from post-menopausal women. With regard to the rhFSH, which least resembled FSH in the follicular phase, the explanation presumably lies in the decreased ability of the Chinese hamster ovary cells to synthesize complex, branched carbohydrate chains. Whatever the explanation the marked difference between the carbohydrate complexity of rhFSH and endogenous follicular FSH seems to be unimportant as Puregon is clearly highly bioactive in vivo.
A comparison of the glycosylation variants of the FSH preparations separated on the basis of charge (Lambert et al., 1995) with those separated by internal carbohydrate complexity has revealed a negative linear relationship between the percentage glycoforms with pi < 4 and the 810 log percentage simple forms. This may be expected since pi of the glycoforms reflects the sialic acid termini of the carbohydrate side chains with increased branching producing more sialic acid termini and therefore a lower pi. Further, de Leeuw et al. (1996) working with purified rhFSH (Puregon) glycoforms of differing pi found that those with a low pi have a high sialic acid/galactose ratio and are rich in tri-and tetra-antennary AMinked carbohydrate chains compared to those with a higher pi. These more acidic glycoforms have had an increased in-vivo half-life since sialylation protects the hormone from rapid clearance from the circulation (Stockell-Hartree and Renwick, 1992) .
To summarize, rhFSH is more basic (Lambert et al, 1995) and has less carbohydrate complexity than all the other preparations (Metrodin, Metrodin-HP, IS 70/45) examined. Although its glycoform distribution is similar to follicular and luteal phase plasma forms with respect to charge it is dissimilar with respect to carbohydrate complexity although this does not appear to seriously influence its invivo bioactivity as this preparation has proven to be highly efficacious in clinical trials. However, if different glycoforms do encode for changed bioactivity and differential function, it should still be the long-term aim to develop rhFSH species which allow for a more physiological approach to assisted reproduction.
